SCHEMBL51361

SCHEMBL51361

COc1ccc(CN2C(C)(C)CN(c3cc(F)ccc3C#N)S2(O)O)cc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AR P10275 3/20 0.40
ALDH1A1 P00352 2/20 0.40
KDM4E B2RXH2 1/20 0.40
FNTA P49354 1/20 0.36
FNTB P49356 1/20 0.36
PGGT1B P53609 1/20 0.36
MAOB P27338 1/20 0.35
SLC22A12 Q96S37 1/20 0.35
MEN1 O00255 2/20 0.35
KMT2A Q03164 2/20 0.35
CHRM4 P08173 1/20 0.34
AMPD2 Q01433 2/20 0.34
HRH1 P35367 1/20 0.34
HTR6 P50406 1/20 0.34
CYP3A4 P08684 1/20 0.34
CYP2D6 P10635 1/20 0.34
MMP1 P03956 1/20 0.34
MMP9 P14780 1/20 0.34
MMP13 P45452 1/20 0.34
ADAM17 P78536 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL51360 0.88 AR (0.42) ARALDH1A1KDM4EFNTAFNTB
SCHEMBL52326 0.78 FFAR4 (0.38) ARSLC22A12AMPD2
SCHEMBL52123 0.72 ALDH1A1 (0.42) ARALDH1A1KDM4EFNTAFNTB
SCHEMBL52325 0.68 FFAR4 (0.38) ARAMPD2CYP2D6
SCHEMBL51440 0.67 FFAR4 (0.37) ARAMPD2
SCHEMBL31496915 0.63 FFAR1 (0.52) MAOBSLC22A12
SCHEMBL51441 0.63 FFAR4 (0.37) ARAMPD2CYP2D6
SCHEMBL24029365 0.61 SIGMAR1 (0.44) ARALDH1A1KDM4EFNTAFNTB
SCHEMBL1461950 0.60 SQOR (0.55) ARALDH1A1KDM4EMAOBMEN1
SCHEMBL29663159 0.60 SQOR (0.55) ARALDH1A1KDM4EMAOBMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2280981-B1 BRIDGED HETEROCYCLES AS HIV INTEGRASE INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2014-04-23 EP disclosed
US-8129398-B2 HIV integrase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2012-03-06 US disclosed
EP-2280981-A1 BRIDGED HETEROCYCLES AS HIV INTEGRASE INHIBITORS Bristol-Myers Squibb Company (US) 2011-02-09 EP disclosed
US-20090253677-A1 HIV Integrase Inhibitors BRISTOL-MYERS SQUIBB COMPANY 2009-10-08 US disclosed
WO-2009117540-A1 BRIDGED HETEROCYCLES AS HIV INTEGRASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2009-09-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090253677-A1 HIV Integrase Inhibitors DNTT, POLB, UNG AR 2036/4885ALDH1A1 539/4885KDM4E 1609/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.